Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

This study is testing a combination of two drugs — gedatolisib (a PI3K/mTOR inhibitor) and darolutamide (a hormone-blocking drug) — for men with prostate cancer that has spread and is no longer responding to standard hormone therapy (castration-resistant prostate cancer). **You may be eligible if...** - You are a man (18 or older) with metastatic prostate cancer that progressed despite standard hormone-suppressing treatments - Your cancer has been confirmed by standard imaging (CT, MRI, or bone scan) - Your PSA level is at least 1.0 ng/mL and has been rising - Your general health (ECOG 0–1) and organ function meet study requirements **You may NOT be eligible if...** - Your cancer has only been detected on a PSMA PET scan (not visible on standard imaging) - You have significant heart disease (NYHA class III or IV) - You have a small-cell or neuroendocrine component to your prostate cancer (>10%) - You have uncontrolled diabetes Talk to your doctor to see if this trial is right for you.